Review Article
Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors
Table 2
Emetogenic potential of oral antineoplastic agents most used in solid tumors (based on NCCN guidelines 2014).
| | NCCN guidelines 2014 | | Degree of emetogenicity (incidence) | Agent |
| | Moderate to high | Hexamethylmelamine | | Crizotinib | | Cyclophosphamide (≥100 mg/m2/day) | | Estramustine | | Etoposide | | Lomustine (single day) | | Mitotane | | Procarbazine | | Temozolomide (>75 mg/m2/day) | | Vismodegib |
| | Minimal to low | Axitinib | | Cabozantinib | | Capecitabine | | Cyclophosphamide (<100 mg/m2/day) | | Dabrafenib | | Erlotinib | | Everolimus | | Gefitinib | | Imatinib | | Lapatinib | | Methotrexate | | Pazopanib | | Regorafenib | | Sorafenib | | Sunitinib | | Temozolomide (<75 mg/m2/day) | | Topotecan | | Trametinib | | Vandetanib | | Vemurafenib |
|
|
